| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/21/2007 | WO2007068637A1 Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
| 06/21/2007 | WO2007068619A1 Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors |
| 06/21/2007 | WO2007068552A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof |
| 06/21/2007 | WO2007068465A1 Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| 06/21/2007 | WO2007068354A1 Means and methods for the treatment of tumorous diseases |
| 06/21/2007 | WO2007068316A1 Hydroxyquinoline derivatives |
| 06/21/2007 | WO2007068188A1 Camptothecin compounds with a substituent located in 10-position comprising multi-carboxyl groups, their preparation processes and their pharmaceutical compositions |
| 06/21/2007 | WO2007068084A1 Novel macrolide compounds with antibiotic and antneoplastic properties |
| 06/21/2007 | WO2007048064A3 Amino-pyrimidines as casein kinase ii (ck2) modulators |
| 06/21/2007 | WO2007047893A3 Use of dasatinib for the treatment of bone metastasis |
| 06/21/2007 | WO2007047291A3 Anti-glypican-3 antibody |
| 06/21/2007 | WO2007028512A3 Magnetic-field controlled active substance transfer for aerosol therapy |
| 06/21/2007 | WO2007027714A3 Engineered anti-il-23 antibodies |
| 06/21/2007 | WO2007019575A3 Methods for treating b-cell malignancies using taci-ig fusion molecule |
| 06/21/2007 | WO2007016340A3 Defective ribosomal products in blebs (dribbles) and methods of use to stimulate an immune response |
| 06/21/2007 | WO2007015757A3 Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators |
| 06/21/2007 | WO2007013666A3 Anti-tumor agents comprising r-spondins |
| 06/21/2007 | WO2006131649A3 Use of fumagillin and the derivatives thereof to increase the bioavailability of the macrocyclic lactones |
| 06/21/2007 | WO2002100330A9 METHODS OF ADMINISTERING ANTI-TNFα ANTIBODIES |
| 06/21/2007 | US20070143871 Non-human transgenic animal models for hepatocellular carcinoma |
| 06/21/2007 | US20070142718 Noninvasive measurement of chemical substances |
| 06/21/2007 | US20070142476 Biphenyl-Derivatives as p38 Kinase Inhibitors |
| 06/21/2007 | US20070142470 Antidiabetic agents, antilipemic agents, dietetics, anticholesterol agents, hypotensive agents, cardiovascular disorders; (S)-Ethyl 2-methoxy-3-[4-{3-(4-methanesulfonyloxyphenyl) propylamino}phenyl]propionate |
| 06/21/2007 | US20070142466 Photoreactive compounds and compositions |
| 06/21/2007 | US20070142465 Macrophage activation inhibitor |
| 06/21/2007 | US20070142459 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections |
| 06/21/2007 | US20070142449 Angiogenesis inhibitors |
| 06/21/2007 | US20070142425 Use of CCI-779 as an antineoplastic agent |
| 06/21/2007 | US20070142393 Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 06/21/2007 | US20070142388 Inhibitors of Akt activity |
| 06/21/2007 | US20070142387 Process for producing folic acid derivatives |
| 06/21/2007 | US20070142377 Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives |
| 06/21/2007 | US20070142375 Pyrrolidine derivatives as factor xa inhibitors |
| 06/21/2007 | US20070142374 e.g. 2-(4-Chlorophenyl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide; blood coagulation factor and trypsin-like serine protease inhibitor; anticoagulant, antiinflammatory agent; atherosclerotic plaque, myocardial infarction and unstable angina |
| 06/21/2007 | US20070142370 Azabicyclooctan-3-one derivatives and use thereof |
| 06/21/2007 | US20070142352 Pteridinone Derivatives as Modulators of Chemokine Receptor Activity |
| 06/21/2007 | US20070142350 Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates |
| 06/21/2007 | US20070142341 Use of steroid derivatives for the treatment of angiotensin ll related disease e.g. cardiovascular and proliferative disorders |
| 06/21/2007 | US20070142338 Tetracycline Derivatives and Methods of Use Thereof |
| 06/21/2007 | US20070142335 e.g. 2-amino-2-methyl-4-{1-methyl-5-[4-(3,4-dimethylphenyl)butanoyl]pyrrol-2-yl}butan-1-ol ; immunology-related disease selected from crohn's disease ulcerative colitis, multiple sclerosis, atopic dermatitis, insulin dependent diabetes mellitus, glomerular nephritis and rejection of a transplanted organ |
| 06/21/2007 | US20070142334 cancer, inflammatory, autoimmune, infectious and viral diseases , destructive bone disorders, proliferative and neurodegenerative disorders; 2-(5-fluoro-2-tolyl)-4-(4-aminocarbonylpiperazinylmethyl)-6-[a-aminocarbonyl-2,6-dichlorobenzyl]pyridine |
| 06/21/2007 | US20070142305 Antitumor agents; restenosis; antiarthritic agents; antidiabetic agents; platelet-derived growth factor receptor (PDGF-R) |
| 06/21/2007 | US20070142294 Identification and cloning of novel human gene, RET16, involved in the intracellular signaling cascade |
| 06/21/2007 | US20070142281 Preventives/remedies for myeloma tumor and method for diagnosing the same |
| 06/21/2007 | US20070142280 Factor VII or VIIa-like molecules |
| 06/21/2007 | US20070141669 Pregnancy-associated plasma protein-A2 (PAPP-A2) |
| 06/21/2007 | US20070141621 Method Of Screening For Sensitivity To Kinase Inhibitor Therapy |
| 06/21/2007 | US20070141620 Producing polyoxyethylene glycol covalently bound to human interferon; antiinflammatory and antitumor agents; autoimmune diseases and infections; conjugation decreases the number of doses for an intended effect, simplify and stabilize the formulation of a composition |
| 06/21/2007 | US20070141619 Drug resistance-associated gene and use thereof |
| 06/21/2007 | US20070141579 MUM-1 protein expressed by multiple myeloma-related gene |
| 06/21/2007 | US20070141140 Semi-solid formulations for immediate release intended for the oral administration of drugs |
| 06/21/2007 | US20070141069 Method for use of IGF-binding protein for selective sensitization of target cells in vivo |
| 06/21/2007 | US20070141061 Protein involved in carcinoma |
| 06/21/2007 | US20070141039 Bifidobacterium longum infantis strain secretes a factor that antagonizes the activity ofpro-inflammatory cytokine selected from TNF- alpha, IL-8, IFN gamma to treat inflammatory bowel disease or irritable bowel syndrome |
| 06/21/2007 | US20070141033 Purging of cells using viruses |
| 06/21/2007 | US20070141026 Immunotherapy in cancer treatment |
| 06/21/2007 | US20070141025 Compositions and methods for cancer immunotherapy |
| 06/21/2007 | US20070140970 Cell targeting conjugates |
| 06/21/2007 | CA2634073A1 Compositions comprising ingenol-3-angelate |
| 06/21/2007 | CA2633908A1 Hydroxyquinoline derivatives useful for the treatment of tumors and cellular proliferation |
| 06/21/2007 | CA2633594A1 Means and methods for the treatment of tumorous diseases |
| 06/21/2007 | CA2633543A1 Antitumour compounds |
| 06/21/2007 | CA2633211A1 Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer |
| 06/21/2007 | CA2633129A1 Alkylsulphonamide quinolines |
| 06/21/2007 | CA2633035A1 Kinase inhibitors and their uses |
| 06/21/2007 | CA2633023A1 Polycyclic indazole derivatives that are erk inhibitors |
| 06/21/2007 | CA2632983A1 Biological materials and uses thereof |
| 06/21/2007 | CA2632618A1 Demethylpenclomedine analogs and their use as anticancer agents |
| 06/21/2007 | CA2632603A1 Dibenzonaphthyridine derivatives and methods of use thereof |
| 06/21/2007 | CA2632466A1 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| 06/21/2007 | CA2632451A1 Cell penetrating peptides for intracellular delivery of molecules |
| 06/21/2007 | CA2632437A1 1,2,4-triazol-1-yl bisphenyl derivatives for use in the treatment of endocrine-dependent tumours |
| 06/21/2007 | CA2631907A1 Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors |
| 06/21/2007 | CA2631853A1 Substituted pyrazolo [4,3-c] pyridine derivatives active as kinase inhibitors |
| 06/21/2007 | CA2631813A1 Bicyclic heterocycles, medicaments containing said compounds, use thereof, and method for the production thereof |
| 06/21/2007 | CA2631641A1 Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib |
| 06/21/2007 | CA2631034A1 Tricyclic lactam derivatives, their manufacture and use as pharmaceutical agents |
| 06/21/2007 | CA2630839A1 Therapeutic methods for inhibiting tumor growth with dll4 antagonists |
| 06/21/2007 | CA2626016A1 Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| 06/20/2007 | EP1798285A1 Methods and medicament for inhibition the expression of a defined gene |
| 06/20/2007 | EP1798243A2 Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors |
| 06/20/2007 | EP1798242A2 New anti-GF-IR antibodies and their applications |
| 06/20/2007 | EP1798236A1 Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof |
| 06/20/2007 | EP1798235A1 Acid addition salt of irinotecan |
| 06/20/2007 | EP1798234A1 Pharmaceutical composition comprising temozolomide ester |
| 06/20/2007 | EP1798230A1 Substituted alkylamine derivatives and methods of use |
| 06/20/2007 | EP1798226A1 Triazole derivative |
| 06/20/2007 | EP1798217A1 Anticancer agents based on regulation of protein prenylation |
| 06/20/2007 | EP1797896A1 Adjuvant systems and vaccines |
| 06/20/2007 | EP1797884A2 Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system |
| 06/20/2007 | EP1797881A1 Medicinal composition |
| 06/20/2007 | EP1797880A2 Use of P53 inhibitors for the treatment of side effects of cancer therapy |
| 06/20/2007 | EP1797877A1 Joint use of sulfonamide based compound with angiogenesis inhibitor |
| 06/20/2007 | EP1797874A1 Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation |
| 06/20/2007 | EP1797427A2 Methods for identifying new drug leads and new therapeutic uses for known drugs |
| 06/20/2007 | EP1797183A2 Regulation of oncogenes by micrornas |
| 06/20/2007 | EP1797171A1 Methods for the generation of hepatocyte-like cells from human blastocyst-derived stem (hbs) |
| 06/20/2007 | EP1797092A1 2-substituted-6-trifluoromethyl purine derivatives with adenosine-a3 antagonistic activity |
| 06/20/2007 | EP1797086A1 Indole derivatives, their manufacture and use as pharmaceutical agents |
| 06/20/2007 | EP1797085A1 Thiazolinone 4-monosubstituted quinolines |